Details :
The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Details :
The funding will enable development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform, to overcome challenges with this target class for the treatment of Autoimmune diseases and Chronic p...
Details :
Under the agreement, PrecisionLife will apply its combinatorial analytics platform to patient datasets to find multiple new therapeutic targets for development by Ono.
Details :
ioGlutamatergic Neurons(MAPT N279K/WT™) Human iPSC-derived FTD disease model,A rapidly maturing, consistent and scalable isogenic system to study frontotemporal dementia (FTD).
Details :
Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have an option to develop any targets identified and to own and commercialise any ...
Details :
Under the agreement, Alchemab and MDC will evaluate antibodies using innovative technologies, including the use of high content imaging, high resolution microscopy, spatial transcriptomics to assess endpoints using induced pluripotent stem cell derived n...
Details :
The strategic collaboration will aim to accelerate drug discovery in neurodegenerative disease, tackling undisclosed targets in a multi-year programme. Denali will be responsible for the further lead optimisation, development, and commercialisation of th...
Details :
Under the terms of the agreement, first announced in 2018, Mission and AbbVie are collaborating to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases.
Details :
The funding will accelerate the clinical development of the proprietary cell coding technology opti-ox - a breakthrough gene engineering approach that enables unlimited batches of human cell to be manufactured consistently at scale through direct reprogr...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 11, 2021
Lead Product(s) :
Human iPSC-derived Glutamatergic Neurons
Details :
The new capital, alongside company's recently announced collaboration with Eisai supports lead small molecule programs targeting amyloid-β and α-synuclein, with first clinical candidate for amyloid-β in Q1 2021.
Reset All
